$3.76
5.76% today
Nasdaq, Apr 03, 06:49 pm CET
ISIN
US23285D1090
Symbol
CTKB

Cytek BioSciences Inc Stock price

$3.99
-0.31 7.21% 1M
-1.25 23.86% 6M
-2.50 38.52% YTD
-2.53 38.80% 1Y
-7.57 65.48% 3Y
-14.77 78.73% 5Y
-14.77 78.73% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.07 1.79%
ISIN
US23285D1090
Symbol
CTKB
Sector

Key metrics

Market capitalization $511.11m
Enterprise Value $260.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 11.94
EV/Sales (TTM) EV/Sales 1.30
P/S ratio (TTM) P/S ratio 2.55
P/B ratio (TTM) P/B ratio 1.30
Revenue growth (TTM) Revenue growth 3.85%
Revenue (TTM) Revenue $200.45m
EBIT (operating result TTM) EBIT $-23.12m
Free Cash Flow (TTM) Free Cash Flow $21.85m
Cash position $277.89m
EPS (TTM) EPS $-0.04
P/E forward negative
P/S forward 2.47
EV/Sales forward 1.26
Short interest 3.84%
Show more

Is Cytek BioSciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Cytek BioSciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Cytek BioSciences Inc forecast:

3x Buy
50%
2x Hold
33%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a Cytek BioSciences Inc forecast:

Buy
50%
Hold
33%
Sell
17%

Financial data from Cytek BioSciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
200 200
4% 4%
100%
- Direct Costs 89 89
8% 8%
45%
111 111
1% 1%
55%
- Selling and Administrative Expenses 84 84
0% 0%
42%
- Research and Development Expense 39 39
11% 11%
20%
-13 -13
30% 30%
-6%
- Depreciation and Amortization 10 10
38% 38%
5%
EBIT (Operating Income) EBIT -23 -23
9% 9%
-12%
Net Profit -6.02 -6.02
50% 50%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Cytek BioSciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytek BioSciences Inc Stock News

Neutral
GlobeNewsWire
16 days ago
FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek® Guava® Muse® cell analyzer, creating a next-generation instrument called the Cytek® Muse® Micro.
Neutral
Seeking Alpha
about one month ago
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Matthew Sykes - Goldman Sachs Chad Wiatrowski - TD Cowen Harrison Parsons - Stephens Inc. Operator Thank you for standing by, and good day, everyone. My n...
Neutral
GlobeNewsWire
about one month ago
FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024.
More Cytek BioSciences Inc News

Company Profile

Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in December 2014 and is headquartered in Fremont, CA.

Head office United States
CEO Wen Jiang
Employees 648
Founded 1992
Website cytekbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today